Search
Now showing items 11-19 of 19
Molecular characterization of cancers with NTRK gene fusions
(
Springer Nature
, 2019 , Article)
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently detected in rare cancer types (e.g., secretory ...
TERT gene fusions characterize a subset of metastatic Leydig cell tumors
(
Elsevier
, 2021 , Article)
Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic ...
The Role of Pathology in the Era of Personalized (Precision) Medicine: A Brief Review.
(
NLM (Medline)
, 2021 , Article)
This review provides a brief overview of the state-of-the-art molecular pathology approaches emphasizing the increasingly important pathology role in clinical precision cancer medicine. Recent advances in molecular biology ...
Nutm1-rearranged neoplasms: A heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations: An updated review
(
MDPI
, 2021 , Article)
Nuclear protein of testis (NUT), a protein product of the NUTM1 gene (located on the long arm of chromosome 15) with highly restricted physiologic expression in post-meiotic spermatids, is the oncogenic driver of a group ...
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
(
Elsevier Ltd
, 2018 , Article)
Background: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for ...
PD-L1 status in breast cancer: Current view and perspectives.
(
Elsevier
, 2019 , Article)
Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ...
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
(
Academy of Sciences and Arts of Bosnia and Herzegovina
, 2022 , Article)
In the present review, we briefly discuss the breakthrough advances in precision medicine using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms of resistance and the diagnostic approach in ...
Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report
(
Elsevier
, 2023 , Article)
Small cell lung cancer (SCLC) is a highly aggressive malignancy with a poor outcome. We present the case of a 57-year-old male patient with extensive-stage (ES-SCLC) treated with chemotherapy and atezolizumab. A complete ...
An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
(
Multidisciplinary Digital Publishing Institute (MDPI)
, 2023 , Article)
Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50. Immune checkpoint inhibitors (ICI) treatment has shown promising results in MCC patients. ...